Research Article| Volume 31, ISSUE 1, P104-106, January 2017

Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men

First Report: Changes in HPV Antibody Titer



      Patients with human papillomavirus (HPV) DNA–positive recurrent laryngeal papillomatosis commonly have repeated recurrences following surgery. The reason is suspected to be a mechanism by which latent HPV infection in the surrounding healthy mucosa reinfects the surgical site. It may be that production of HPV antibodies in the laryngeal mucosa with Gardasil injection could inhibit postoperative recurrence.

      Study Design

      This is a case series study.


      The purpose of this study was to examine whether Gardasil injection effectively inhibits recurrence. However, as a first report, we describe the antibody titers before and after vaccination.


      Gardasil was injected in 12 men (aged 32–74 years; mean age 47.9 years) with HPV-positive laryngeal papillomatosis. Serum antibody titers of HPV-6, -11, -16, and -18 were measured by a competitive Luminex-based immunoassay before the vaccination and 7 months after the start of the vaccination.


      Each of the antibody titers was very low before vaccination, and they rose in all patients after the vaccination.


      This finding demonstrates that antibody titers increase with Gardasil injection in post-adolescent males.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Voice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gissmann L.
        • Diehl V.
        • Schultz-Coulon H.J.
        • et al.
        Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma.
        J Virol. 1982; 44: 393-400
        • Terry R.M.
        • Lewis F.A.
        • Griffiths S.
        • et al.
        Demonstration of human papillomavirus types 6 and 11 in juvenile laryngeal papillomatosis by in-situ DNA hybridization.
        J Pathol. 1987; 153: 245-248
        • Makiyama K.
        • Hirai R.
        • Matsuzaki H.
        • et al.
        Assessment of human papilloma virus infection in adult laryngeal papilloma using a screening test.
        J Voice. 2013; 27: 230-235
        • Maloney E.M.
        • Unger E.R.
        • Tucker R.A.
        • et al.
        Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis.
        Arch Otolaryngol Head Neck Surg. 2006; 132: 711-715
        • Chen B.B.
        • Zhao K.N.
        • Liu X.S.
        • et al.
        [The detection and significance of human papilloma virus 11b virus like particles and its serum antibody in juvenile larynx papilloma].
        Zhonghua Er Bi Yan Hou Ke Za Zhi. 2003; 38: 417-420
        • Förster G.
        • Boltze C.
        • Seidel J.
        • et al.
        [Juvenile laryngeal papillomatosis—immunisation with the polyvalent vaccine Gardasil].
        Laryngorhinootologie. 2008; 87: 796-799
        • Pawlita M.
        • Gissmann L.
        Recurrent respiratory papillomatosis: indication for HPV vaccination?.
        Deutsch Med Wochenschr. 2009; 134: S100-S102
        • Munoz N.
        • Manalastas Jr, R.
        • Pitisuttithum P.
        • et al.
        Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial.
        Lancet. 2009; 373: 1949-1957
        • Hillman R.J.
        • Giuliano A.R.
        • Palefsky J.M.
        • et al.
        Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
        Clin Vaccine Immunol. 2012; 19: 261-267
        • Nobbenhuis M.A.
        • Walboomers J.M.
        • Helmerhorst T.J.
        • et al.
        Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study.
        Lancet. 1999; 354: 20-25
        • Clavel C.
        • Masure M.
        • Bory J.P.
        • et al.
        Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.
        Br J Cancer. 2001; 84: 1616-1623
        • Ronco G.
        • Giorgi-Rossi P.
        • Carozzi F.
        • et al.
        Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial.
        Lancet Oncol. 2006; 7: 547-555
        • Yoshikawa H.
        • Kawana T.
        • Kitagawa K.
        • et al.
        Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers.
        Jpn J Cancer Res. 1991; 82: 524-531
        • Dias D.
        • Van Doren J.
        • Schlottmann S.
        • et al.
        Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.
        Clin Diagn Lab Immunol. 2005; 12: 959-969